HC Wainwright Reiterates “$160.00” Price Target for Sarepta Therapeutics (NASDAQ:SRPT)

Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT) received a $160.00 price target from analysts at HC Wainwright in a research note issued to investors on Friday, TipRanks reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 86.05% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. BidaskClub cut shares of Sarepta Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 27th. Morgan Stanley boosted their target price on shares of Sarepta Therapeutics from $165.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Cantor Fitzgerald reduced their target price on shares of Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating for the company in a research report on Tuesday, August 20th. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating for the company in a research report on Tuesday, August 20th. Finally, Credit Suisse Group dropped their price target on Sarepta Therapeutics from $207.00 to $201.00 and set an “outperform” rating for the company in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $191.83.

Sarepta Therapeutics stock traded down $1.98 during midday trading on Friday, hitting $86.00. 983,067 shares of the stock were exchanged, compared to its average volume of 2,252,563. The company has a fifty day simple moving average of $114.63 and a two-hundred day simple moving average of $125.47. Sarepta Therapeutics has a 52 week low of $83.62 and a 52 week high of $165.87. The stock has a market capitalization of $6.54 billion, a PE ratio of -15.75 and a beta of 2.19. The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The business had revenue of $94.67 million during the quarter, compared to analyst estimates of $91.05 million. During the same quarter last year, the business earned ($1.67) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 28.8% on a year-over-year basis. As a group, equities research analysts anticipate that Sarepta Therapeutics will post -4.94 EPS for the current fiscal year.

In other Sarepta Therapeutics news, Director Michael W. Bonney purchased 2,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was purchased at an average price of $86.74 per share, for a total transaction of $173,480.00. Following the transaction, the director now owns 7,051 shares in the company, valued at approximately $611,603.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director M Kathleen Behrens purchased 2,500 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were acquired at an average price of $87.98 per share, with a total value of $219,950.00. Following the transaction, the director now owns 123,167 shares in the company, valued at approximately $10,836,232.66. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 30,752 shares of company stock valued at $3,502,664. 6.60% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Enlightenment Research LLC increased its stake in Sarepta Therapeutics by 199.9% in the 2nd quarter. Enlightenment Research LLC now owns 5,200 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 3,466 shares during the period. Sit Investment Associates Inc. grew its position in shares of Sarepta Therapeutics by 42.4% in the 1st quarter. Sit Investment Associates Inc. now owns 22,065 shares of the biotechnology company’s stock worth $2,630,000 after buying an additional 6,575 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Sarepta Therapeutics by 8.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 306,409 shares of the biotechnology company’s stock worth $46,559,000 after buying an additional 24,932 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its position in shares of Sarepta Therapeutics by 1.7% in the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 992,371 shares of the biotechnology company’s stock worth $118,281,000 after buying an additional 16,666 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Sarepta Therapeutics by 150.3% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 75,180 shares of the biotechnology company’s stock worth $9,755,000 after buying an additional 45,149 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: What is insider trading?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.